Otsu/Shiga, Japan – May 19, 2015 - Takara Bio Inc. announced that it is selected as a contract corporation for a grant in fiscal 2015, “Project Focused on Developing Key Evaluation Technology: Evaluation for Industrialization in the Field of Regenerative Medicine”, by Ministry of Economy, Trade and Industry and Japan Agency for Medical Research and Development (AMED).
The purpose of this project is to facilitate commercialization of excellent seeds in new technology fields such as regenerative medicine. For this purpose, establishment of methods to assess safety and conformity of the technologies is essential . Under this project, Takara Bio will develop methods to evaluate safety and efficacy of technologies for CD19・CAR gene therapies.
Takara Bio will promote development of CD19・CAR gene therapy under this project and aim to start a clinical trial in Japan in this fiscal year.
|Project||Project Focused on Developing Key Evaluation Technology: Evaluation for Industrialization in the Field of Regenerative Medicine in fiscal 2015|